上海市2011～2015年含无细胞百日咳、白喉和破伤风成分联合疫苗预防接种安全性评价

发布时间：2018-01-12 00:06

本文关键词：上海市2011～2015年含无细胞百日咳、白喉和破伤风成分联合疫苗预防接种安全性评价　出处：《中国疫苗和免疫》2016年02期 　论文类型：期刊论文

【摘要】：目的评价上海市含无细胞百日咳、白喉和破伤风联合疫苗(DTaP)成分的联合疫苗预防接种安全性。方法通过中国疑似预防接种异常反应信息管理系统收集2011~2015年上海市报告的DTaP、DTaP-b型流感嗜血杆菌联合疫苗(DTaP-Hib)和DTaP-灭活脊髓灰质炎-Hib联合疫苗(DTaP-IPV-Hib)的AEFI数据,通过上海市免疫规划信息系统收集接种数据,采用描述流行病学方法进行分析。结果 2011~2015年上海市报告DTaP一般反应15 938例,报告发生率为369.34/10万剂;异常反应322例,报告发生率为7.46/10万剂。报告DTaP-Hib一般反应364例,报告发生率为362.63/10万剂;异常反应7例,报告发生率为6.97/10万剂。报告DTaP-IPV-Hib一般反应6 331例,报告发生率为1 009.59/10万剂;异常反应75例,报告发生率为11.96/10万剂。在一般反应和异常反应报告发生率上,DTaP-IPV-Hib与DTaP、DTaP-Hib差异有统计学意义,而DTaP和DTaP-Hib差异无统计学意义。三种疫苗异常反应均以过敏性皮疹为主,合计报告发生率为7.88/10万剂;而其他严重异常反应合计报告发生率为0.36/10万剂,主要发生在第1剂和加强免疫后。结论三种含DTaP成分联合疫苗安全性均良好,DTaP和DTaP-Hib的不良反应报告发生率低于DTaP-IPV-Hib。
[Abstract]:Objective to evaluate acellular pertussis in Shanghai. Diphtheria and tetanus combined vaccine DTaP). Methods the DTaP reported from Shanghai from 2011 to 2015 was collected through China suspected vaccination abnormal response Information Management system. AEFI data of Haemophilus influenzae type DTaP-b combined vaccine (DTaP-Hib) and DTaP- Hib vaccine (DTaP-IPV-Hib). The inoculation data were collected by Shanghai Immunization Planning Information system and analyzed by descriptive epidemiology. Results from 2011 to 2015, 15 938 cases of DTaP general reaction were reported in Shanghai. The reported incidence was 369.34 / 100 million doses; Abnormal reaction was reported in 322 cases, the reported rate was 7.46 / 100 000 doses, and the general reaction of DTaP-Hib was reported in 364 cases, and the reported incidence rate was 362.63 / 100 million doses. Abnormal reaction was reported in 7 cases, the reported rate was 6.97 / 100 000 doses, the general reaction of DTaP-IPV-Hib was 6 331, and the reported incidence was 1 009.59% / 100 000 doses. There were 75 cases of abnormal reaction, the reported rate was 1196 / 100 000 doses. DTaP-IPV-Hib and DTaP were detected in general reaction and abnormal reaction reporting. The difference of DTaP-Hib was statistically significant, but there was no significant difference between DTaP and DTaP-Hib. The abnormal reactions of the three vaccines were mainly allergic rash. The total reported incidence was 7.88 / 100, 000 doses; However, the total reported incidence of other severe abnormal reactions was 0.36 / 100 000 doses, mainly after the first dose and after booster immunization. Conclusion the safety of the three combined vaccines containing DTaP is good. The incidence of adverse reactions in DTaP and DTaP-Hib was lower than that in DTaP-IPV-Hib.
【作者单位】：上海市疾病预防控制中心;
【基金】：上海市第四轮公共卫生三年行动计划重点学科建设项目-传染病与卫生微生物学(编号:15GWZK0101)
【分类号】：R186
【正文快照】： 联合疫苗是未来疫苗发展的方向[1],可以有效减少受种者的接种频次、剂次,减轻接种工作者的工作量,提高工作效率,提高疫苗接种率,从而有效防范传染病的流行。吸附无细胞百白破联合疫苗(Diphthe-ria,Tetanus and Acellular Pertussis Combined Vaccine,DTa P)、DTa P-b型流感嗜

【相似文献】